Erschienen in:
01.08.2015 | Thoracic Oncology
Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma
verfasst von:
Rintaro Yoshida, MD, PhD, Masaru Morita, MD, PhD, Fumihiro Shoji, MD, PhD, Yuichiro Nakashima, MD, PhD, Naoko Miura, MD, PhD, Keiji Yoshinaga, MD, PhD, Tadashi Koga, MD, PhD, Eriko Tokunaga, MD, PhD, Hiroshi Saeki, MD, PhD, Eiji Oki, MD, PhD, Yoshinao Oda, MD, PhD, Yoshihiko Maehara, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2015
Einloggen, um Zugang zu erhalten
Abstract
Background
Epithelial-mesenchymal transition (EMT), when epithelial cells convert to mesenchymal cells, influences cancer invasion and metastasis. Smad interacting protein 1 (SIP1) is an EMT trigger, which is inversely correlated with E-cadherin in some carcinomas. To elucidate the role of SIP1 in esophageal squamous cell carcinoma (ESCC), the status of EMT and the clinicopathological features were evaluated.
Methods
Immunohistochemical (IHC) analyses of 111 human ESCC tissue specimens for SIP1 and E-cadherin were performed, and the relationships between the expression and clinicopathological features were evaluated.
Results
IHC analyses of esophageal tumors showed the expression of SIP1 and E-cadherin to be significantly inversely correlated. Significant correlations between the SIP1 expression and clinicopathological variables such as differentiation, depth of invasion, vascular invasion, and pathological stage were also seen. Conversely, tumors with a weak expression of E-cadherin tended to exhibit greater histological differentiation. Logistic regression analyses revealed a positive SIP1 expression, lymphatic invasion, and vascular invasion to be factors predicting lymph node (LN) metastasis. Univariate survival analyses revealed a positive SIP1 expression predicted a poorer overall survival than a negative expression.
Conclusion
These results suggest that SIP1 is correlated with LN metastasis and may therefore be an independent marker for metastasis in patients with ESCC.